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StlmmlLry 
The differentiating agent retinoic acid (R.A) has been previously reported to interfere with 12- 
O-tetradecanoyl-phorbol-13-acetate (TPA)/CaZ+-induced signals for the regulation of the  -96 
to -66-bp octamer motif found in the enhancer for the interleukin (IL)-2 gene, which encodes 
a major T lymphocyte growth factor. The IL-2 octamer motif is a composite c/s-element which 
binds Oct-1  and Oct-2  as well as  a  TPA/Ca2+-inducible nuclear factor,  previously termed 
octamer-associated protein (OAp4~  We show here that Oct-2, despite the presence of an active 
transcriptional activation domain, requires TPA/CaZ+-induced signals to strongly transactivate 
the IL-2 octamer motif in Jurkat T cells. This Oct-2-dependent transactivation is inhibited by 
PA.  The  presence  of  an  intact  COOH-terminal  domain  of  Oct-2  contributes  to  both 
TPA/Ca2+-induced transactivation and the pA-mediated repression.  We also show that both 
Fos andJun  components of the AP-1 factors participate in the OAP  4~ complex. Furthermore, 
transfected c-jun, jun-B, jun-D, c-fos, or Fos-B expression vectors partially substitute for TPA and 
Ca  2+  and cooperate with Oct-2  for  the transactivation of the combined OAP/octamer c/s- 
element. Mutations of the genuine octamer-binding site abrogate both the binding of Oct-1 
and Oct-2 and the TPA/Ca  2+-induced transactivation of the OAP/octamer motif. OAP confers 
to  Oct-2  responsivity  to  both  TPA/Ca  2+  and  PA,  since  specific  mutations  of  the  AP- 
1/OAP-binding site significantly reduce the transactivation by Oct-2 in response to TPA and 
Ca  2+ and abolish the inhibition by RA. Furthermore, retinoic acid receptor (PAR) o~ is able 
to inhibit in vitro the formation of the complex between the nuclear AP-1/OAP and its specific 
binding site, resulting in the interference with Oct-2-dependent c/s-regulatory function of this 
AP-1 element. Therefore, we propose that the TPA/calcium-activated AP-1/OAP element is the 
main target of positive or negative regulatory signals influencing the IL-2 octamer motif, through 
synergism with Oct-2 and antagonism by PAR. 
l~ 
tinoic acid  (PA)l  exerts  a wide variety of effects on 
embryonic development, cell ditferenthtion, and growth 
through regulation of growth factors and homeotic genes 
and protooncogenes (1-7). Retinoids bind to several receptors 
1 Abbreviations used in this paper: CAT, chloramphenicol  acetyltransferase; 
EMSA, electrophoretic  mobility shift assay; GR, ghcocorticoid receptor; 
NFAT, nuclear factor of activated T cells; PKC, protein kinase C; RA, 
retinoic acid; RAK, retinoic acid receptor; RARE-E, KAR-responsive 
element of the RARB promoter; RRL, rabbit reticulocyte  lysate; RXR, 
retinoid X  receptor; tk,  thymidine kinase; TPA, 12-O-tetradecanoyl- 
phorbol-13-acetate. 
(e.g., retinoic acid receptors [RAP,] c~,/~, and 3` and retinoid 
X receptor [RXR] or,/3, and 3' and their isoforms), which 
combine with each other to form a variety of dimers able 
to bind and transactivate  specific c/s-elements of target genes 
(for review see reference 8). The range of genes controlled 
by retinoids is further broadened by the ability of PAR and 
RXR to control the expression of genes encoding other trans- 
acting factors, such as the homeotic Hox genes, nuclear pro- 
tooncogenes, and the development-related octamer-binding 
proteins (1, 4, 6, 9-12).  This latter class of proteins belongs 
to the POU family of transacting factors characterized  by 
a homeodomain DNA-binding region (13, 14). Transcrip- 
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occurs through antagonism or synergism with distinct fami- 
lies of transacting factors, including AP-1 (15-21; for review 
see reference 22). 
The influence of RAP, on lymphoid T cell differentiation 
and growth is suggested by the ability of RA to modulate 
the expression of the human and murine IL-2 genes, which 
encode a major T lymphocyte growth factor (23, 24) involved 
in the control of T  cell development (25,  26).  The use of 
retinoids as therapeutic agents and the subsequent potential 
immunosuppression and influence on development underline 
the importance of elucidating their regulatory role in the IL-2 
gene. The IL-2 promoter contains several control elements, 
which mainly require a variety of transacting factors activated 
by protein kinase C (PKC) and calcium-mediated signals (for 
reviews see references 27 and 28). We have previously reported 
that one target of the RAp`-mediated inhibition of the PKC- 
and calcium-mediated activation of the IL-2 enhancer is an 
octamer motif at a position  - 96 to  - 66 bp upstream of the 
start site (23). This motif binds the inducible nuclear factor(s) 
OAP  4~ whose composition includes jun protein (29, 30), as 
well as both Oct-l- and Oct-2-transacting  factors (29, 31, 
32), which are, therefore, potential targets of RA-mediated 
regulation.  Whereas Oct-1 is ubiquitous, Oct-2 has a more 
restricted pattern of cell distribution,  being expressed in B 
cells and in some T  cells (31, 32). Furthermore,  both trans- 
acting factors are regulated by stimuli that activate the IL-2 
gene (29, 31,  32). Specifically,  Oct-2 levels are upregulated 
by antigen  stimulation  in  some T  cells  (32). 
The presence of distinct Oct factors regulating cytokine 
gene expression suggests that  they might be responsive to 
differential regulatory pathways. Indeed,  distinct  transcrip- 
tional requirements for Oct-1 and Oct-2 have been reported. 
Whereas Oct-1 is competent in enhancing transcription from 
snRNA promoters, it requires supplementation by auxiliary 
factors, which provide transcriptional activation domains (e.g., 
the herpes virus VP16 protein harbors a strong acidic trans- 
activation domain)  to activate mp`NA promoters (13,  33). 
In contrast,  Oct-2 harbors a strong COOH-terminal  tran- 
scriptional activation domain for mp`NA promoters, which 
when replacing  the Oct-1 COOH terminus, can provide tran- 
scriptional activation (13, 34). The OAP  4~ complex may rep- 
resent auxiliary factors required for Oct-1 function.  How- 
ever, the requirements of Oct-2 for the regulation of the IL-2 
promoter remain  to be elucidated. 
In this study we have addressed the molecular events im- 
plicated in the Oct-2-dependent activation and P,A-induced 
downregulation of the octamer motif of the IL-2 enhancer. 
We show that the IL-2 octamer motif is a composite binding 
site for Oct-2 and afis- andjun-containing  AP-1 complex, 
whose functional cooperation is required to fully enhance tran- 
scription. P,AP,cx is able to inhibit the formation of the AP- 
1-DNA complex in vitro, resulting in an interference with 
the Oct-2-dependent c/s-regulatory function of this AP-1 ele- 
ment.  Therefore, the AP-1 element appears to be the main 
target for positive or negative regulatory signals that influence 
the IL-2 octamer motif, either through cooperation with Oct-2 
or antagonism  by RAP,. 
Materials and Methods 
Plasmid Constructs.  The  plasmid  pIL2CAT  contains  the  IL- 
2-flanking region from - 575 to + 47 bp driving the chloramphen- 
icol acetyltransferase (CAT) gene (35). All reporter constructions 
based on the pBLCAT2 vector were prepared by use of a vector 
in which the AP-1 site in the plasmid backbone had been deleted, 
as previously described (17). IL-2-OAP/OCT-tk-CAT  was con- 
structed by inserting four copies of the proximal (-96 to -66-bp) 
Ib2 octamer motif into either the pBIg2AT2 vector (36) (including 
the octamerless [- 105-bp] thymidine kinase [tk] promoter driving 
the CAT gene) or the (-37-bp) tk-CAT vector (37), as previously 
described (23). All of the plasmids containing mutated (m) or deleted 
(A) sequences of the ID2 octamer motif (described in Fig. 6) were 
prepared in the same way. Wild-type deletion  mutants  and chi- 
meric forms of Oct-1 and Oct-2 cDNAs, cloned in pCG expres- 
sion vector containing the human CMV promoter, were provided 
by Dr.  W. Herr (Cold Spring Harbor Laboratory, Cold Spring 
Harbor, NY) (34). pRcKSV-OCT2 was constructed by inserting 
the Oct-2 cDNA in the pRcRSV vector (Invitrogen,  San Diego, 
CA). Expression vectors encoding hKARc~ and its mutant forms 
(A1-81 and A81-152) and RXR~x were provided by Dr. P. Chambon 
(Laboratoire de G6n&ique Mol&ulaire des Eucaryotes du CNKs, 
Strasbourg, France) and Dr. K. Evans (Howard Hughes Medical 
Institute)  (19, 38). The plasmid tk-TREp2-CAT contains the RA- 
responsive element driving the CAT gene through the tk promoter 
(39). pAP-lcoll-tk-CAT contains five copies of the collagenase AP- 
1 site in front of the tk promoter (40). JMneo (c-Jos expression 
vector), J~s-Bneo 0~s-B expression vector),  their  control  vector 
pRAXneo, and expression vectors for c-jun and jun-B under  the 
control  of the Rous sarcoma virus (RSV) promoter (KSV c-jun 
and RSVjun-B) and their control vector pUC-RSV were as previ- 
ously described (41-44). Thejun-D expression vector, containing 
jun-D cDNA under the control of the CMV promoter in the pCMV- 
1 vector, has been previously described (17). 
Cell Culture and DNA Transfection.  The human Jurkat T cell 
lines (T-77 clone and a subclone partially resistant  to RA) were 
cultured in RPMI 1640 medium supplemented with 10% FCS and 
antibiotics (50 IU/ml penicillin and 50 #g/ml streptomycin; Flow 
Laboratories, Ayrshire, Scotland). HeLa cells were grown in DMEM 
(Flow Laboratories) supplemented with 10% FCS and antibiotics 
as described above. Jurkat cells were treated with 30 ng/ml  12- 
O-tetradecanoyl-phorbol-D-acetate  (TPA), 1/~g/ml A23187 or 2 
#g/ml ionomycin (Sigma Chemical Co.,  St. Louis, MO), in the 
presence or absence of 1/~M RA (Sigma Chemical Co.). 
Transfection of  Jurkat cells were carried out either by the DEAE 
dextran method as previously described (23, 45) or by electropora- 
tion. In the latter case, phsmid DNA mixtures were, added to 107 
Jurkat  cells/ml medium without serum and antibiotics and elec- 
troporated in a gene pulser apparatus (Bio-Rad Laboratories, Rich- 
mond, CA) using 350 V and 960/iF capacitance, and then further 
cultured in complete growth medium. All cells were cotransfected 
with plasmid pCH110 (Pharmacia, Uppsala, Sweden) as an internal 
control for transfection ef~ciency. 24 h after transfection, cells were 
treated with the drugs indicated above. After a further 24 h, cells 
were harvested and protein extracts were prepared for the CAT and 
B-galactosidase assays, as previously  described (23).  Data were 
quantified by autoradiography and liquid scintillation counting and 
normalized to the levels of B-galactosidase expression of cotrans- 
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of transfected  Oct proteins were monitored by gel retardation assays 
and Western blotting (by use of anti-Oct-1 and -Oct-2 antibodies, 
described in reference 46). 
Nuclear Extracts.  Nuclear extracts from Jurkat T cells  were pre- 
pared by a modification of a previously described technique (47). 
Cells were lysed by homogenization in 10 mM Hepes, pH 7.9, 
10 mM KCI, 1.5 mM MgC12, I mM EDTA, 1 mM dithiothreitol, 
1 mM PMSF, 10% glycerol, and 0.2% NP-40. Nuclei were cen- 
trifuged at 1,000  g and resuspended in two volumes of the above- 
described solution.  KC1 was added to a final concentration of 
0.39 M, and nuclei were extracted at 4~  for I h and centrifuged 
at 100,000 g for 30 rain. The supematants were dialyzed against 
20 mM Hepes, pH 7.9, 50 mM KC1, 1 mM PMSF, 1 mM DTT, 
and 20% glycerol, the debris removed  by centrifugation, and stored 
at  -80~  Nuclear extracts from HeLa cells were prepared by 
homogenizing cells in 10 mM Hepes, pH 7.9, 1.5 mM MgClz, 
10 mM KC1, 0.5 mM PMSF, and 0.25 mM DTT. Nuclear frac- 
tions were extracted  in 20 mM Hepes, pH 7.9, 20% glycerol,  0.42 M 
NaC1, 0.2 mM EDTA, 1.5  mM MgC12, 0.25 mM DTT, and 
0.5 mM PMSF, dialyzed against 20 mM Hepes, pH 7.9, 50 mM 
KC1, 1 mM PMSF, 1 mM DTT, and 20% glycerol, and cell debris 
were removed by centrifugation. 
In Vitro Translation.  RNA templates  for in vitro translation  reac- 
tions of  hKARoe, hRXRcr  Oct-l, and Oct-2 were generated from 
plasmids (pGEM3) containing  the  cDNAs  by SP6 polymerase 
(Promega Biotec, Madison, WI) and translated in vitro with rabbit 
reticulocyte lysate (RILL) according to the manufacturer's recom- 
mendation. 
Bacterial Expression of RARer Protein.  Full-length  hRARoe 
cDNA was inserted  into pRSET B vector (Invitrogen) and expressed 
in Escherichia coli BL21(DE3)plysE. A  single colony of E.  coli 
BL21(DE3)plysE transformed with pRSET B-RAKot was grown 
in Luria broth with ampicillin (100 #g/ml) and chloramphenicol 
(30/zg/ml) at 37~  until cell density reached an OD~ of 0.7. 
Isopropyl-~-n-thiogalactopyranoside  (IPTG; Sigma Chemical Co.) 
was added to final  concentration 0.4 mM for 3 h to induce hRARot 
protein expression. Recombinant protein was then purified  on resin- 
charged columns (ProBond; Invitrogen) according to the manufac- 
turer's recommendation. KAKor protein was verified by Western 
immunoblot analysis  using anti-RARc~  primary antibody Ab9c~(hF) 
(provided by Dr. Chambon) diluted 1/1,500, as described (48). 
Electrophoretic Mobility Shift Assay.  32p-labeled  probes (0.4 ng, 
50,000 cpm) were incubated with 10 #g nuclear extracts of  Jurkat 
cells for 20 min at room temperature in 15 mM Hepes, pH 7.9, 
2.5 mM MgC12, 2 mM DTT, 40 mM KC1, 4% glycerol, and 2-5 
#g poly(dl-dC) (Sigma Chemical Co.). Anti-pan-fis (provided by 
Dr. M. Iadarola, National Institutes of  Health, Bethesda, MD) (49) 
or anti-pan~/un antibodies (Santa Cruz Biotechnology Inc., Santa 
Cruz, CA) were incubated with nuclear extracts for 1.5 h at 4~ 
after binding reactions, described above. In other experiments, 5 
#g Jurkat nuclear extracts and/or 5/zl in vitro synthesized RAKcr 
and RXRoe or bacterially expressed KAKoe proteins were prein- 
cubated with 1 #g poly(dl-dC) in 10 mM Hepes, pH 7.9, 1 mM 
DTT, 2.5 mM MgC12, 10% glycerol, and a range of KC1 concen- 
trations of 10, 40, and 100 mM for 15 rain on ice. After the addi- 
tion  of the KAR-responsive element of the  RAR3 promoter 
(RARE3; 50) or OAP/OCT probe, the reaction mixtures were 
incubated for a further 25 min at room temperature. Anti-KAKc~ 
antibody Abgc~(hF) was incubated with the mixture for 15 min 
at 4~  after the binding reaction. All binding reactions were per- 
formed in a final volume of 20 #1. Protein-DNA complexes  were 
separated from free probe by gel electrophoresis on 4% polyacryl- 
amide gels in 0.25x  TBE buffer (0.23 M Tris-borate, 1 mM EDTA, 
pH 8.0) at 150 V for 1.5 h at room temperature. Gels were dried 
and exposed to film (XAK-5; Eastman-Kodak, Rochester, NY) at 
-80"C. 
Results 
TPA and Calcium  Ionophore-rnediated Induction of Oct-2- 
dependent Activation of the IL-2 0ctarner Motif and Its Antagonisrn 
by RA.  Activation of intact (-300 bp) IL-2 enhancer and 
the -96 to  -66-bp IL-2 octamer motif fused to a heterolo- 
gous tk promoter was demonstrated in Jurkat cells transfected 
with Oct-2 expression vector after treatment with TPA and 
ionomycin (Fig. 1). Transactivation of the IL-2 enhancer and 
IL-2 octamer motif  driving either the -105-bp tk or the -37- 
bp tk promoters was significantly stronger inJurkat cells trans- 
fected with Oct-2 expression vector after TPA and ionomycin 
treatment than that caused by endogenous Oct-1 in cells trans- 
fected with empty pCG vector (Fig.  1 A). Accumulation of 
nuclear Oct-2-IL-2 octamer complex could be demonstrated 
in cells devoid of endogenous Oct-2 transfected with pCG- 
Oct2 vector, which encodes Oct-2 under the control of the 
CMV promoter (Fig.  1 B). The levels of this complex were 
augmented 10-20-fold by TPA and ionomycin treatment due 
to upregulation of the CMV promoter (Fig.  1, A  and B). 
This drug-induced augmentation in Oct-2 levels alone would 
not appear to contribute to IL-2 octamer motif transactiva- 
tion as CAT activity in the absence of TPA and ionomycin 
treatment was not significantly increased, despite similar levels 
ofintracellular Oct-2 protein (Fig. 1, B and C; compare CAT 
activity and intracellular Oct-2 levels in cells transfected with 
0.2/zg pCG-Oct-2 and treated with TPA/ionomycin to those 
transfected with 5/zg pCG-Oct-2 in the absence of TPA/ 
ionomycin). Similar results were obtained when Oct-2 ex- 
pression vector driven by the KSV promoter (KSV-Oct2) 
was transfected into Jurkat cells, which was not significantly 
influenced by TPA/ionomycin (51; Fig.  1 A). This would 
suggest a requirement for additional TPA/ionomycin-induced 
coregnlatory signals in Oct-2-mediated transactivation of oc- 
tamer motif. TPA/ionomycin-induced  Oct-2-dependent trans- 
activation of both the intact IL-2 and the  -96 to  -66-bp 
IL-2 octamer motif was significantly inhibited by RA (Fig. 
1 A). As KA neither inhibited the activity of the CMV pro- 
moter, used to drive Oct-2 transcription (Fig.  LA), nor de- 
creased the levels of Oct-2 protein resulting from transfec- 
tion (Fig. 1 D), the inhibitory activity of KA likely resulted 
from interference with TPA/ionomycin-induced  coregnlatory 
signals.  These data suggest that the  -96 to  -66-bp  IL-2 
octamer motif is the focal point for both RA-mediated inac- 
tivation and the TPA/ionomycin-mediated  cofactor require- 
ment of Oct-2-dependent IL-2 transactivation. 
Delineation of TPA/Ionornycin  and RAR-responsive Domains 
in Oct-2.  To study the domains of the Oct-2 protein that 
are involved in TPA/ionomycin-induced transactivation and 
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the  IL-2 octamer  motif.  (A) 
Graphic representation of the fold 
induction of CAT activity com- 
pared with basal levels in CAT 
assays performed  on cell lysates 
prepared ftom Jurkat cells  cotrans- 
fected with  IL-2-CAT (row  1), 
OAP/OCT(-105)-tk-CAT  (row 
2), OAP/OCT(-37)-tk-CAT (row 
3),  (-105)-tk-CAT  (row  4),  or 
(-37)-tk-CAT  (row  5)  cotrans- 
fected either with (+) or without 
(-) pCG vector (pCG) or pCG- 
Oct-2 expression vector (Oct.2). 
CAT activity was also assayed in 
cell  lysates prepared  from  cells 
cotransfected  with  OAP/OCT 
(-105)-tk-CAT vector and either 
pReRSV empty vector or Oct-2 
encoding  pReRSV-vector (RSV 
Oct2) (row 6) or transfected with 
CMV-CAT alone (row 7) or ILSV- 
CAT alone (row 8). All cells  were 
transfected with 5/zg of the above- 
described CAT vectors plus 1 #g 
RAKa expression  vector. Extracts 
in all cases were prepared 24 h after 
treatment  with  medium  alone 
([~), TPA and ionomycin (VA), or 
TPA and ionomygin in the pres- 
ence of 1/zM RA([I). All treat- 
ments were performed 24 h after 
transfection~ Results are expressed 
as mean (•  from three to six 
experiments)  fold  induction of 
CAT activity observed in drug- 
treated  versus  -untreated  cells 
(basal). Basal CAT activity values (expressed as pmol/h/mg protein) in the absence or in the presence of Oct-2, respectively, were as follows: 45  • 
8 and 55  •  9 (in cells transfected with II..2-CAT); 120  •  15 and 190  •  30 (in cells transfected with IL2OAP/OCT(-105)tk-CAT);  55  •  7 and 
80  •  6 (in cells transfected with IL2OAP/OCT(-37)tk-CAT);  110  •  10 and 105  •  15 (in cells transfected with -105tk-CAT); and 60  •  4 and 55 
•  5 (in cells transfected with - 37tk-CAT). (/3) Representative EMSA of Oct-2 octamer complexes in  Jurkat cell nuclear extracts prepared after transfec- 
tion with increasing amounts (0.2-5/,g) of pCG-Oct-2 expression vector as indicated and incubation for 4 h either in medium alone (-) or in the 
presence of TPA and ionomycin (+). Binding  reactions contained either nuclear extracts, in vitro translated Oct-2 protein (RRL+ Oct2), or unprogrammed 
RRL and 32p-labeled  AOAP/OCT oligonucleotide  probe ATATGTAAAACATTT (see also Fig. 6). Arrows indicate specific Oct-1 and Oct-2 DNA 
complo~es. Results shown are representative of two similar experiments. (C) Graphic representation of CAT activity assayed in cell extracts prepared 
from Jurkat cells, cotransfected with OAP/OCT(-105)-tk-CAT  reporter and increasing amounts of pCG-Oct-2 vector, 24 h after treatment with (O) 
or without (O) TPA and ionom3min.  (D) Representative EMSA showing the effect of RA on octamer complexes in  Jurkat cell nuclear extracts prepared 
from cells transfected with pCG vector alone (+pCG) or with pCG-Oct-2 expression vector (+Oct2) after 4 h treatment with TPA and ionomycin 
in the absence (-) or presence (+) of 1/zM RA. Displacement of specific Oct complexes by a 50-fold excess of unlabeled competitor  AOAP/OCT 
oligonucleotide  (competitor +) is also shown. Last two lanes show binding reactions containing unprogrammed RRL or in vitro translated Oct-2 
(RRL+ OCT2), respectively. A 32p-labeled  AOAP/OCT oligonucleotide  probe was used. 
in the inhibitory activity of R.A, we cotransfected several  con- 
structs encoding Oct-2 and Oct-1 proteins carrying deletions 
in the NH2-  or COOH-terminal  regions or chimeric pro- 
teins  together  with  the  IL-2-OAP/OCT-(-10S)tk-CAT 
reporter (Fig.  2).  The levels  of expression  and integrity of 
these transfected wild-type mutant Oct-2 and Oct-2 proteins 
in each transfection were monitored by electrophoretic  mo- 
bility shift assay (EMSA) of nuclear extracts from an aliquot 
of transfected cells. The complexes observed in EMSA were, 
in each case, consistent with expression of the fuU-length pro- 
tein (Fig. 2 B). The analysis of the transfected Oct-2 and Oct-1 
proteins by EMSA showed that all mutant or chimeric pro- 
teins accumulated within the cells to comparable levels under 
basal conditions and after TPA/ionomycin or RA treatments 
(Fig. 2 B). Oct protein levels analyzed by Western immuno- 
blotting (with anti-Oct-2 and anti-Oct-1 antibodies; 46) cor- 
responded to those determined by EMSA (data not shown). 
Similar  TPA/ionomycin-induced transcriptional  activation 
function and repression by RA was observed with Oct-2 pro- 
teins  deleted  of the proximal (94 amino acids,  Oct-2AN1) 
or distal (adjacent glutamine-rich 62 amino acids, Oct-2AN2) 
NH2-terminal  regions compared with the wild-type protein 
(Fig.  2 A). 
In contrast, deletion of the COOH terminus from residue 
358 to the end (including a putative leucine zipper; Oct-2AC) 
decreased the transacting function (as evaluated by transfec- 
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by wild-type, mutant, and chimeric Oct-1 and Oct-2 proteins. (A) Jurkat 
cells were cotransfected with 5 #g IL-2-OAP/OCT(-105)tk-CAT,  1 /zg 
RARot, and 1/~g of either the wild-type,  mutant, or chimeric forms of 
the two Oct proteins, depicted on the left. Cells were treated with TPA 
and ionomycin  and processed for CAT assay as described in Fig. 1. CAT 
activities relative to untreated (basal) cells transfected with pCG vector 
are represented.  Basal levels in pCG-transfected  cells were  100  +  15 
pmol/h/mg protein. CAT activities were normalized to the levels  of trans- 
fected Oct proteins (considering the ratio between the protein levels and 
the CAT activity described in Fig. 1, A and B) and evaluated by EMSA 
of nuclear extracts from an aliquot of the cells. Results shown represent 
the average of three similar experiments  (differing <20% from one an- 
other).  (B) EMSA of the various wild-type and mutant Oct proteins ob- 
served in nuclear extracts from an aliquot of cells described in A. Assay 
and treatment conditions are as described in Fig. 1. 
tion over a range of 0.5-5/zg plasmid) (Fig.  2 A  and data 
not shown). Likewise,  the antagonistic activity of RA on 
Oct-2AC was almost lost (Fig. 2 A). Surprisingly, transfection 
of the Oct-1 expression vector resulted in repression of the 
TPA/ionomycin-induced  activation of the IL-2-OAP/OCT- 
tk-CAT construct. Whereas the Oct-2 COOH terminus was 
required for enhancer transactivation, the inhibitory activity 
of Oct-1  also mapped to the COOH  terminus, according 
to data recently reported by Annweiler et al. (52) for the B 
cell-specific  enhancer stimulation.  In fact,  transfection of 
Oct-I/Oct-2 chimeric constructs indicated that whenever the 
Oct-1 COOH  terminus was present in the fusion protein 
(Oct-2.1.1,  Oct-1.2.1, Oct-2.2.1), the transactivation of the 
octamer CAT was repressed (Fig. 2). Chimeric proteins con- 
taining the Oct-1 NH2 terminus with Oct-2 POU domain 
and COOH  terminus (Oct-1.2.2) or Oct-1  POU domain 
and Oct-2 COOH terminus (Oct-l.L2) (transfected  over a 
range of 0.5-5/~g plasmids) had comparably lower activity 
than  Oct-2  NH2  terminus-containing proteins  (Fig.  2). 
They were, however, fully antagonized by RA. All of these 
data  taken  together  show  that  an  intact  Oct-2  COOH- 
terminus contributes to both the TPA/ionomycin-mediated 
activation  and  RA-induced  inhibition,  suggesting  that 
TPA/caldum and RA signal through an overlapping pathway. 
To investigate this pathway, we studied the nuclear factors 
binding to the octamer motif. 
Characterization of the Composite IL-2 0ctamer Motif: Pres- 
ence of an AP-I  Complex and Transcriptional  Activation by fos 
andjun.  In addition to Oct-1 and Oct-2, a TPA/calcium- 
inducible nuclear factor, previously termed OAP  4~ has been 
reported to bind to a region dosdy linked to the  -96  to 
-66-bp IL-2 octamer-binding site (29). The OAP binding 
site shares five out of seven nudeotides with a canonical AP- 
1 binding motif (Fig. 3 A). The complex between the IL-2 
octamer motif deleted from the  Oct binding site  (OAP/ 
AOCT) and nuclear factors extracted from TPA/ionomycin- 
activated Jurkat T  cells was displaced by competition with 
an excess of either unlabeled collagenase AP-1 (Fig. 3 B, APt 
Coil) or the proximal (-160 to  -139-bp) AP-1 site of the 
IL-2 promoter (not shown), which has been shown to bind 
jun and los proteins in activated T  cells (21, 53).  An unla- 
baled OAP/AOCT also competed  for proteins from activated 
T  cells that bind to an AP-1 site from the collagenase pro- 
moter (Fig. 3 B, OAP). Similar resuhs were observed with 
HeLa cell nuclear extracts as a source of AP-1 factor (Fig. 3 B). 
We also observed that antibodies against both los andjun 
proteins were able to bind to the complex formed by nuclear 
factors (from both  Jurkat and HeLa cells) and the OAP/AOCT 
sequence motif, whereas an unrelated antibody was uneffec- 
tire (Fig. 3 C and data not shown). This result suggests that 
the protein complex that binds to the OAP/AOCT sequence 
containsfis andjun family members, which are components 
of AP-1. The OAP/AOCT sequence not only binds an AP-1 
factor, but its c/s-regulatory function is also activated byjun 
andjSs. Fig. 4 shows that cotransfection of vectors encoding 
either c-jun,jun-B, orjun-D with pCG-Oct-2 (Oct2) in the 
absence of TPA/ionomycin treatment could partially substi- 
tute for PKC and calcium-mediated signals in the transacti- 
vation of the IL-2-OAP/OCT-tk-CAT reporter. Similar trans- 
activation was observed by cotransfecting Oct-2 with c-fis 
or Fos-B, which are likely to form heterodimer complexes 
with the endogenousjun-D,  which has been recently reported 
1489  de Grazia et al. Figure  3.  Detection  ofjun/fos/AP-1 factors  binding to the II.-2 octamer motif in Jurkat cell nuclear  extracts. (A) EMSA of nuclear extracts from 
Jurkat cells treated with or without TPA and ionomycin,  binding to the OAP/OCT oligonucleotide  represented on the bottom in the absence or 
presence  of a 50-fold  excess  of  unlabeled  OAP/OCT  competitor  oligonucleotide.  Arrowheads  indicate  the Oct-1 complex  alone  or the combined  OAP/Oct-1 
supershifted complex. (B) EMSA of unstimulated  Jurkat and HeLa  cell and 4-h TPA/calcium-stimulated  Jurkat cell nuclear  extracts binding to either 
the OAP site  deleted  of octamer sequences (OAP/AOCT, described  in Fig. 6) or the AP-1 consensus  sequence  from  the collagenase  promoter (AP-lcoll, 
5'-GATCCGGCTGACTCATCA-Y).  A 50-fold  excess  of unlabeled  OAP or AP-lcoll  (B) competitor  oligonucleotides  were  included  in the binding  reac- 
tion as indicated  above each lane. Arrowheads  indicate  the specific  TPA/Ca  2  ~  -inducible AP-1 complex. (C') EMSA of nuclear extracts  from either un- 
treated  or TPA/ionomycin-treated  (for  4 h)  Jurkat cells  incubated  with labeled  OAP/AOCT  probe for 30 rain and then  further  incubated  with antibodies 
against either los (c~-Fos),  jun (ot-jun)  or/J-galactosidase  (~-13 gal) proteins. Fos and jun antibodies  recognize  all members of theJbs andjun families, 
respectively. Arrowheads  indicate  either the specific AP-1 complex  or a complete or partial supershfft  of the TPA/ionomycin-inducible  complex by 
et-Jbs and ot-jun, respectively.  Additional  complexes  moving  faster than OAP band (shown in B and C) represent nonspecific  complexes, as determined 
by competition using several competitor oligonucleotides  (including  nonspecific  and self-competitors)  as well as different  amounts of Poly(dl-dC). 
to be constitutively  expressed inJurkat cells (54). No significant 
increase in CAT activity was observed  whenjun  andJbs ex- 
pression vectors were transfected in the absence of the Oct-2 
vector (Fig.  4,  pCG). 
The OAP c/s.Element  Slmergizes with the Oct-20ctamer Com- 
plex and is Negatively Regulated by RAR.  The ability olios 
andjun to synergize with Oct-2 in enhancing the IL-2 oc- 
tamer motif suggests that both elements may be required to 
drive transcription. To address this point, we introduced mu- 
tations or deletions in either or both OAP- and OCT-binding 
sites and tested their c/s-regulatory activity on a heterologous 
tk promoter. We first studied the binding specificity of these 
sequences versus OAP, Oct-l, and Oct-2 proteins by testing 
their ability to compete for binding to radiolabeled OAP/OCT 
or OAP/AOCT probes.  Oligonucleotides carrying substi- 
tution mutations  or  a  deletion  of the  OAP  binding  site 
(mOAP/OCT and AOAP/OCT,  respectively)  competed, as 
well as the wild-type OAP/OCT motif for in vitro trans- 
lated Oct-2 (Fig. 5 A, lanes 4-6) or endogenous Oct-1 (Fig. 
5 B, lanes 2, 4, and 5), but they did not bind the OAP factors 
(Fig. 5 B, lanes 4, 5, 14, and 15). Mutations or deletions of the 
octamer-binding sequence (OAP/mOCT and OAP/AOCT, 
respectively) abolished the DNA-binding ability of Oct-2 and 
Oct-1  (Fig.  5 A, lanes  7 and 8 and Fig.  5 B, lane 3),  but 
they still allowed binding of the OAP factors (Fig. 5 B, lanes 
3,  12, and 13). An analysis of the functional activity of the 
mutated c/s-regulatory motifs indicated that four copies  of 
the double-mutated OAP/OCT element (m(OAP/OCT)-tk- 
CAT),  OAP/mOCT  (OAP/mOCT-tk-CAT),  or  OAP/ 
AOCT  (OAWAOCT-tk-CAT)  driving  CAT  expression 
through a tk promoter were unable to be transactivated by 
Oct-2 in response to TPA and ionomycin treatment (Fig. 6). 
This result suggests that the AP-l-binding OAP element has 
weak enhancer activity in the absence of concomitant Oct-2 
binding. The abrogation of OAP binding (mOAP/OCT-tk- 
CAT and AOAP/OCT-tk-CAT) also impaired the ability of 
the octamer motif to be transactivated by Oct-2 in response 
to TPA and ionomycin by "~90% (Fig. 6 B). This result sug- 
gests that Oct-2 has very weak enhancer activity in response 
to TPA and ionomycin without concomitant AP-1 binding. 
Thus, both c/s-elements  appear  to require mutual coopera- 
tion for full enhancer properties. Of further interest is the 
observation that mutation or deletion of the OAP binding 
motif almost completely abrogated the ability to RA to an- 
tagonize the TPA/ionomycin-induced Oct-2-dependent ac- 
tivation of the IL-2 octamer binding site;  this is probably 
due to the very low TPA/ionomycin-induced activation ob- 
served. Thus, RA inhibition was observed only when both 
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Figure 4.  Transactivation of the IL-2-OAP/OCT c/~-element  byjun or 
]os and Oct-2 expression vectors in unactivated Jurkat cells. Empty vectors 
(pR~Xneo, pUC-RSV,  or pCMV-1), c-jun,jun-B,  jun-D, c-fos, or Fos-B 
expression vectors were cotransfected together with II~2-OAP/OCT-tk- 
CAT and either pCG-Oct2 or pCG plasmids into Jurkat cells. Where in- 
dicated, cells were treated 24 h later with TPA and ionomycin (TPA + 
Ion). CAT assays in cell extracts were carried out 48 h after transfection. 
Results are expressed as the average (_+SE from three experiments) fold 
increase of the CAT activity observed compared with untreated empty 
vector-translated cells (basal activity 125 _+ 20 and 180 _+ 30 pmol/h/mg 
protein,  in the absence and presence of Oct-2, respectively). 
Figure 5.  Binding specificity of OAP/OCT motif through competition assays using oligonucleotides carrying mutations or deletions in the OAP 
(raOAP/OCT  and &OAP/OCT, respectively), octarner (OAP/mOCT and OAP/AOCT, respectively), or both sites [m(OAP/OCT)].  Mutated oligonu- 
cleotides are described in Fig. 6. (A) EMSA of in vitro synthesized Oct-2 protein (RRL + Oct2,  arrowhead)  or unprogrammed RRL binding  to labeled 
OAP/OCT probe. The 50-fold excess of  unlabded competitor oligonucleotides are indicated above  each lane. Arrowhead indicates the Oct-2 protein-DNA 
complex. (B) EMSA of nuclear extracts from Jurl~t cells stimulated  with TPA and ionomycin  for 4 h, binding  to either OAP/OCT or the OAP sequence 
alone (OAP/AOCT) as probes. For the competition assays, a 50-fold excess of the unlabeled oligonucleotides indicated above each lane (including a 
nonspecific sequence (N$)]  were used. RRL and RRL+Octl indicate the complex formed by in vitro synthesized Oct-1 protein as described in Fig. 
1. Arrowheads  indicate the Oct-1  or OAP complexes alone or the combined OAP/Oct-1 supershifted complex. 
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ILZ-OAP/OCT :  TTGAAAATATGTGTAA T ATGTAAAACKI-FT 
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IL2-AOAP/OCT :  .........................  A  T ATGTAAAACATTT 
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IL2-0AP/0CT  ~ CM 
m(IL2-0AP/0CT)  tk CAT 
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Figure 6.  Functional analysis of Oct-2 transactivating activity in respon- 
sive sequences mutated either in the OAP (IL2-AOAP/OCT-tk-CAT, IL 
2-raOAP/OCT-tk.CAT), octamer (IL2-OAP/AOCTtk-CAT, Ib2-OAP/ 
raOCT--de.CAT),  or both sites (m[IL2-OAP/OCT]-tk-CAT). (A) Descrip- 
tion of the mutated oligonudeotides cloned as four-copy concatemers in 
front of the (-105)-tk-CAT fusion reporter. (B) Each reporter phsmid shown 
in A or APlcoll-tk-CAT (4 ~tg) was cotransfected into Jurkat cells together 
with pCG-Oct-2 and RARcx (1/tg) expression vectors. After 24 h, ceils 
were treated with TPA and ionomycin or RA as indicated in Fig. 1 and 
further processed for CAT assay 24 h later. Results  are expressed as the 
average (_+SE from three experiments)  fold increase of the CAT activity 
observed in drug-treated  relative to untreated (basa/) ceils after subtraction 
of the CAT activity expressed in the absence of transfected Oct-2. Basal 
CAT activity values (praol/h/rag  protein) were 160  +_  25 (IL2OAP/OCT- 
tie-CAT);  100  +  20  (m[IL2-OAP/OCT]tkCAT); 138  +  15  (11.,2- 
AOAP/OCT-de-CAT), 127  _+  6 (IL2-mOAP/OCT-de-CAT),  94  •  8 (lb 
2-OAP/AOCT-tk-CAT), 80 +_ 15 (IL,2.0AP/raOCT:d~-CAT),  and 52  + 
5 (APIcolI-tle-CAT). 
OAP- and Oct-2-binding sites were allowed to synergize with 
each other. 
PAR has been shown to antagonize the collagenase AP-1 
enhancer  activity in HeLa  cells (18, 19). Thus,  a similar 
PAIL-AP-1 antagonism might occur at the IL-2-OAP motif 
in T  cells. We therefore  studied  the effect of PA on the 
TPA/ionomycin-induced  activation of five copies of the col- 
lagenase AP-1 c/s-element  driving CAT transcription through 
the tk promoter. Fig. 6 B shows that RA treatment resulted 
in a decrease of the TPA/ionomycin-induced activation of 
AP-I-coU-tk-CAT cotransfected with an RARcz expression 
vector into Jurkat cells. 
RARol Inhibits OAP Binding Activity in Vitro.  To study 
the  RARcz  domains  involved in  the  antagonism  of the 
TPA/ionomycin-induced  activation of OAP/OCT c/s-elements, 
we examined the effects of RARot mutant expression vectors 
[]  -  RA 
￿9  +RA 
No PAR 
1  462 
RARer 462~ 
RAR A  1-81 
RARA81-153 0  20  40  so  80  Ioo  12o 
TPNIon-induced IL2-0AP/OCT-CAT activity 
0  10  20  30 
TREp2CAT  activity 
Figure  7.  The RARo~ DNA- 
binding domain is necessary for 
the R.A-mediated  repression of the 
IL-2 octaraer motif. W'dd-type and 
deletion mutants (1 #g) of RARo~ 
receptor were cotramf~'ted either 
with IL-2-OAP/OCT-tk-CAT  (4 
/zg) or TREp2-CAT (4/.tg) in an 
RA-resistant Jurkat cell subdone. 
On  the  left,  the  wild-type 
(RARo0,  amino  (A1-81),  and 
DNA-binding (A81-153) deleted 
receptors are schematically illus- 
trated. Numbers over the various 
receptors indicate amino acid po- 
sitions,  and  the  filled  box 
represents the DNA-binding do- 
main. The cells were treated and processed for CAT assay as previously described. Results are expressed as CAT activity relative to the 100% TPA/ionomycin- 
induced activation  of IL-2-OAP/OCT-tk-CAT in the absence of KA treatment. Similar levels of TPA/ionomyein-induced IL-2-OAP/OCT-tk-CAT  ac- 
tivity in the absence of RA treatment were observed in untransfected  cells and cells transfected with the various RAP. expression vectors. For TR.Ep2- 
CAT, results are expressed as RA-induced fold activation of CAT activity relative to R.A-untreated cells. The various RAP. expression vectors did not 
influence the TKEp2-CAT activity in the absence of RA treatment.  Results  shown represent  the average (_+SE) of three  experiments. 
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OAP/OCT-tk-CAT in the presence of CMV-Oct-2 cotrans- 
fected into an tLA-resistant Jurkat subclone.  Truncation of 
the NH2 terminus of the receptor did not affect the inhibi- 
tory activity on OAP/OCT-tk-CAT  expression and only 
slightly decreased the RA-induced activation of TREp2-CAT 
reporter, carrying an RA-responsive element driving CAT 
gene  transcription  (Fig.  7).  In  contrast,  ddetion  of the 
receptor DNA-binding domain significantly reduced both 
RA-mediated repression of the TPA/ionomycin-induced  ac- 
tivation of OAP/OCT-tk-CAT and enhancement of TREp2- 
CAT expression (Fig.  7).  This suggests that direct DNA 
binding of RARa  to the IL-2 sequences may be required 
for the effect on OAP/OCT c/s-regulatory  function. To ad- 
dress this point further, we tested the ability of in vitro syn- 
thesized, or bacterially expressed, recombinant RARot to bind 
to the  -96 to  -66-bp OAP/OCT IL-2 sequences in addi- 
tion to the RAREB. According to data previously reported 
(55,  56),  RARa protein acquired RAREB DNA-binding 
activity after  complementation with  in  vitro  synthesized 
RXRo~: the presence of the receptor in the complex with 
RAREB was confirmed  by use of an anti-RAR antibody (Fig. 
8 C,  left panel), lanes 4, 6, and not shown). Interestingly, 
the complementation  of RAR with nuclear extract from both 
untreated or TPA/ionomycin-activated  Jurkat cells also con- 
ferred a distinct pattern of RAREfl DNA-binding activity, 
which was supershifted by the anti-KAR antibody (Fig. 8 
C,  left panel,  lanes 9,  1I,  and not shown). This suggested 
that, in nuclear extracts, different cofactors were present that 
cooperate with receptor for DNA binding. In contrast, com- 
plementation with either RXRa or these different putative 
cofactors present in nuclear extract from both untreated or 
TPA/ionomycin-activated  Jurkat cells was unable to confer 
the in vitro OAP/OCT motif DNA-binding ability to syn- 
thesized or bacterially expressed RARa proteins over a range 
of salt concentrations or DNA-binding incubation conditions 
(Fig.  8  C,  right panel,  lanes  5,  6,  and  not  shown).  The 
OAP/OCT motif was only capable of forming a complex 
Figure 8.  RARc~ does not bind the OAP/OCT motif but inhibits OAP-binding  activity in vitro. (A) SDS-PAGE  of [3sS]methionine-labeled  RXRa 
and RARa translated by RRL (RRL  + RXRa  or RRL  +  RARa)  or unprogrammed RILL. (B) Western immunoblotting of purified bacterially 
expressed RARot protein or the same amount of mock bacterial lysate. (C) DNA-binding  ability (solid arrowheads) of in vitro synthesized RARa alone 
or complemented  with either RXRa (lane 4 in leftpanel  and lane 5 in right panel) or nuclear extract  (N.E.; lane 9 in lefipanel  and lane 6 in rigkt 
panel) from untreated Jurkat cells. Binding reactions were carried out using either labeled RAREB (5'-GATCCGGGTAGGGTTCACCGAAAGTTC- 
ACTCGA-3')  (left panel) or II~2-OAP/OCT (right panel) oligonucleotides,  in the absence or presence (left Pand,  lanes 5 and 13; rigkt Panel, lane 7) 
of a 50-fold excess of unlabeled probe as self-competitor (s.a). Protein complexes with either labeled RAREB or IL-2-OAP/OCT probes after addition 
of anti-RARo~ (a-RAR)  (left panel, lanes 6 and I1;  rigkt panel, lane 9) or anti-B-galactosidase (a-Bgal),  (left Panel, lanes 7 and 12; right Panel, lane 
8) antibodies to the binding reactions are also shown (open arrowkeads). The binding  of RXRa alone or unprogrammed RRL alone or in combination 
with nuclear extract is also represented. The specific complex between nuclear extract and the OAP/OCT probe is represented by Oct-1  (anvw). (D) 
RARoe inhibits OAP binding in vitro. Nuclear extracts of TPA/ionomycin-stimulated  Jurkat cells were incubated with labeled OAP/OCT probe in 
the absence (-) or presence of increasing amounts (1-6/zl) of bacterially expressed RARa (lanes 5-7) or the same amounts of mock bacterial lysate 
(lanes 2-4).  Arrowheads  indicate the Oct-1  complex alone or the combined OAP/Oct-1  (OAP)  supershifted complex. 
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either untreated or TPA/ionomycin activated cells, but not 
PAR, as confirmed by its insensitivity to anti-RAR anti- 
body (Fig. 8 C, right panel, lane 9 and not shown). In con- 
trast,  the  addition of recombinant PARer  inhibited the 
amount of the supershifted complex formed  by OAP and Oct-1 
nuclear factors and the OAP/OCT DNA motif (Fig. 8 D, 
lanes 5- 7). The complex formed by nuclear Oct-1 alone and 
DNA  was  not  affected  by  PARol  (Fig.  8  D).  Mock- 
transformed bacterial lysate did not affect the formation of 
either complex (Fig.  8 D, lanes 2-4). 
Discussion 
Jun and fos Participate in the OAP Octamer Complex and 
Cooperate with Oct-2  for Transacting  Function.  We report here 
that Oct-2 is a very weak transactivator of the IL-2 octamer 
motif  in the absence of phorbol ester and calcium ionophore, 
despite the presence of an active transcriptional activation do- 
main. This would suggest a requirement for both PKC- and 
calcium-induced  coregulatory signals in T cells. The require- 
ment of coreguhtory signals for Oct-2 transcriptional activity 
has also been recently reported in B cells. These signals, which 
are specific for B cells and absent in HeLa cells, appear  to 
be accounted for by the presence of OCA-B factors, which 
interact with Oct-2 (57). Similar data have also been reported 
for E1A, which provides transcription activation function to 
Oct-4 via protein-protein interaction in embryonic stem cells 
(58). Thus, transactivation properties of Oct-2 and Oct-4 ap- 
pear to result from the ability of specific cell types to provide 
cooperating factors that give them functional competence. 
In addition to these recently identified coactivators,  we re- 
port here that another of the cell-specific factors  that can 
cooperate with Oct-2 is the AP-1 complex in T  cells. We 
suggest also that the presence of the AP-1 factor underlies 
the requirement for extracellular regulatory signals (PKC and 
calcium ionophore) in Oct-2-mediated transactivation in T 
cells. In this respect, we have further characterized the previ- 
ously described OAP  4~ complex, which binds to a region 
closely linked to the octamer motif in the IL-2 promoter (29) 
as containing an AP-1 complex. Our data confirm the re- 
cently reported presence ofjun in the OAP  4~ complex (30). 
In addition, we show the presence  of immunoreactive fos 
protein(s) in the OAP  4~ complex. Furthermore, we show 
that overexpression of jun and fos proteins cooperate with 
Oct-2 for the transactivation of the IL-2 octamer motif, and 
that this cooperation is strictly required for full enhancer ac- 
tivity. The presence of an active transcriptional activation do- 
main within Oct-2 suggests that the ability of AP-1 and other 
coregulatory factors to impart functional transcriptional com- 
petence to Oct-2 does not simply provide a transcriptional 
domain for a protein that lacks it, as in the case of VP16- 
Oct-1  interactions (13, 33). 
We have mapped a part of the TPA/calcium-induced  trans- 
acting function of Oct-2 to the COOH terminus, a region 
rich in heptad leucine repeats with the potential to form a 
"leucine zipper"-like structure. It remains to be elucidated 
whether this region is capable if interacting with leudne zipper 
regions injun and fos proteins. We also observed differential 
transactivation of the OAP c/s-element by distinct members 
of thejun andfos family, withjun-B and Fos-B being the most 
active. The composition of the AP-1 factors cooperating with 
distinct transacting factors,  such as Oct-1 and Oct-2, may 
therefore by influential in determining the transacting func- 
tion of the final complex. This may explain the different trans- 
activating function ofjun-B reported in this study compared 
with that described previously (30). Such a selection for AP-1 
complexes of different composition has previously been de- 
scribed for AP-1 cooperation with the nuclear factor of acti- 
vated T  cells (NFAT) motif of the IL-2 enhancer (59-61). 
RARc~ Impairs the Oct-2-clependent AP-1/OAP Function. 
Mapping of the Oct-2 domains required for TPA/calcium- 
induced activation function revealed that they overlapped the 
region required for negative regulation by RARoL. This sug- 
gests that a focus for both activator and inhibitor signals may 
occur on a unique pathway. We show here that this pathway 
could be represented by the AP-1 complex. Abrogation of 
AP-1 binding to the OAP c/s-element blunted the antagonistic 
activity of RAR. An indirect modulation of IL-2 promoter 
by PAR on AP-1/OAP function was suggested by the re- 
quirement for the receptor DNA-binding domain but not 
direct in vitro binding to the IL-2 octamer motif and by the 
ability of PAILct to inhibit the AP-1 binding activity to the 
IL-2-OAP/OCT sequence in vitro. A similar mechanism has 
been proposed for PAR antagonism of collagenase AP-1 cis- 
dement by an inhibition of the AP-1 complex DNA-binding 
activity in HeLa cells independently  from direct PAP, binding 
to DNA (18, 19, 62). We used a similar model to demon- 
strate inhibition of TPA-induced activation of collagenase AP-1 
c/s-regulatory  activity by PARot in T  cells. Therefore, al- 
though the in vivo binding of PAR to the OAP/OCT motif 
cannot be ruled out, the ability of the receptor to inhibit 
the OAP binding activity without direct DNA binding in 
vitro, presented here, is sufficient to suggest that PAR in- 
hibits the functional synergism between AP-1 and Oct factors 
by preventing the binding ofjun andfis to the OAP binding 
site. An appropriate genetic context for AP-1 regulation seems 
to be required, as PA does not interfere with the activity 
of the AP-1 complex found in the NFAT element of IL-2 
enhancer (23, 63). Our data leave open, however, the question 
of the potential contribution of Oct factors in the negative 
regulation of AP-1 sites by RAR and their potential interac- 
tion with the receptor.  In this respect, it should be noted 
that protein-protein interactions have been implicated in both 
the antagonism of Oct-2 function by glucocorticoid receptor 
(GIk; 64) and the synergism between GR and Oct-1 (65). 
It is of further interest that the repression of the IL-2-OAP/ 
OCT motif  by RA, described here, is not without similarity 
to a recent report describing PAR-mediated interference with 
the activation of the calcitonin/calcitonin gene-related pep- 
tide enhancer by cell-specific helix-loop-helix and octamer 
proteins in combination (66). Another nuclear receptor (GR) 
has been described to cause a similar impairment of the func- 
tional cooperation between distinct c/s-elements (AP-1 and 
NFAT) in the IL-2 enhancer (21). 
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Development.  Octamer-binding proteins containing homeo- 
domains are developmentally regulated and involved in the 
cascade of events controlling morphogenic processes (14). As 
RA regulates octamer-binding  proteins  (9-12)  and IL-2 is 
active in T cell development (25, 26), it is possible that PAR 
and  octamer-binding  factors  might  combine  to  modulate 
thymocyte differentiation through regulation of cytokine gene 
transcription.  This hypothesis is consistent with our obser- 
vation that PA can modulate T  cell precursor development 
in an in vitro thymocyte differentiation system (67, 68). To 
extend this hypothesis, the data described here and dsewhere 
(30, 59-61,  63) suggest a central role for AP-1 sites in the 
functional organization of the IL-2 enhancer, which is corn- 
posed of several regulatory modules, including an AP-1 site 
that potentially cooperates with another closely linked trans- 
acting factor-binding motif. This site may well be respon- 
sible for differential regulation by external stimuli. The role 
of AP-1 in regulating  Oct-2 and mediating  RAR activity 
would strongly suggest that it may also contribute to the 
T  cell differentiation process. Support for this comes from 
observations that changes in the AP-1 pathway accompany 
the induction of T cell tolerance (69) and thyrnocyte ontogeny 
(70). As AP-1 responds to a broad range of activating stimuli, 
often unrelated to differentiation pathways, this transcription 
factor may provide signals that  specify developmental pro- 
grams on the basis of selective functional interactions with 
differentiation-related  transacting  factors. 
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